Bristol-Myers Squibb Company
Anti-GITR antibodies for cancer diagnostics
Last updated:
Abstract:
Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
Status:
Grant
Type:
Utility
Filling date:
2 Jun 2016
Issue date:
23 Jun 2020